Spencer Lindeman

Spencer Lindeman, Ph.D., is the Director of Medicinal Chemistry at Eradivir since August 2025, where responsibilities include advancing the BAiT platform for various disease indications through target identification, molecular design, and preclinical development. In June 2025, Spencer founded Lindeman Biotech Consulting and previously served as a Senior Research Scientist at Immunome, Inc. from October 2023 to April 2025 following its merger with MorphImmune, where Spencer worked as a Senior Scientist and Consultant from August 2021. Academic experience includes a postdoctoral researcher and visiting scholar role at Purdue University, focusing on ligand-targeted drug development from November 2015 to January 2023. Spencer's background also includes roles at IBC Advanced Technologies, the National Renewable Energy Laboratory, and Brigham Young University, supporting research in various capacities. Spencer holds a Ph.D. in Chemistry from Purdue University and a Bachelor's Degree in Biochemistry from Brigham Young University.